780 related articles for article (PubMed ID: 19718047)
1. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
2. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
3. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
[TBL] [Abstract][Full Text] [Related]
4. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
5. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
6. Preferential down-regulation of phospholipase C-beta in Ewing's sarcoma cells transfected with antisense EWS-Fli-1.
Dohjima T; Ohno T; Banno Y; Nozawa Y; Wen-yi Y; Shimizu K
Br J Cancer; 2000 Jan; 82(1):16-9. PubMed ID: 10638960
[TBL] [Abstract][Full Text] [Related]
7. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
8. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
Lessnick SL; Braun BS; Denny CT; May WA
Oncogene; 1995 Feb; 10(3):423-31. PubMed ID: 7845667
[TBL] [Abstract][Full Text] [Related]
9. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
[TBL] [Abstract][Full Text] [Related]
10. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.
Thompson AD; Teitell MA; Arvand A; Denny CT
Oncogene; 1999 Sep; 18(40):5506-13. PubMed ID: 10523827
[TBL] [Abstract][Full Text] [Related]
11. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.
Wang M; Xie Y; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
Exp Cell Res; 1999 Jan; 246(1):38-46. PubMed ID: 9882513
[TBL] [Abstract][Full Text] [Related]
12. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
13. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity.
Jaishankar S; Zhang J; Roussel MF; Baker SJ
Oncogene; 1999 Sep; 18(40):5592-7. PubMed ID: 10523836
[TBL] [Abstract][Full Text] [Related]
14. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
15. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
16. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
Soldatenkov VA; Trofimova IN; Rouzaut A; McDermott F; Dritschilo A; Notario V
Oncogene; 2002 Apr; 21(18):2890-5. PubMed ID: 11973649
[TBL] [Abstract][Full Text] [Related]
18. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.
Ouchida M; Ohno T; Fujimura Y; Rao VN; Reddy ES
Oncogene; 1995 Sep; 11(6):1049-54. PubMed ID: 7566963
[TBL] [Abstract][Full Text] [Related]
19. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
Sorensen PH; Lessnick SL; Lopez-Terrada D; Liu XF; Triche TJ; Denny CT
Nat Genet; 1994 Feb; 6(2):146-51. PubMed ID: 8162068
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias.
Yi H; Fujimura Y; Ouchida M; Prasad DD; Rao VN; Reddy ES
Oncogene; 1997 Mar; 14(11):1259-68. PubMed ID: 9178886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]